Q32 Bio
Clinical-stage biotechnology company developing therapies targeting the complement and cytokine pathways to treat autoimmune, inflammatory, and other serious diseases.
Website
https://www.q32bio.comLocation
Cambridge, Massachusetts, USA
Founded
2018
Investors
1
Categories
biotech, autoimmune, immunology, complement-system
Notes
Q32 Bio is a clinical-stage biotechnology company developing therapies that target the complement and cytokine pathways to treat autoimmune, inflammatory, and other serious diseases. The company's approach focuses on modulating these key immune pathways to restore balance in patients with immune-mediated conditions.
Q32's pipeline includes programs targeting multiple autoimmune and inflammatory disorders with significant unmet medical need.
Team
- Jeb Keiper - Chief Executive Officer
- Michael Rosenblum, M.D., Ph.D. - Co-founder & Chief Scientific Officer
Additional Research Findings
- Founded in 2018 in Cambridge, Massachusetts
- Portfolio company of Abingworth
- Focus on complement and cytokine pathway modulation
- Multiple clinical programs in autoimmune diseases
- Lead candidate ADX-097 for immune-mediated conditions
- Backed by top-tier healthcare investors
- Cambridge-based biotech in immunology space
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |